ZOLPIMIST
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOLPIMIST (ZOLPIMIST).
Zolpidem is a nonbenzodiazepine hypnotic that binds selectively to the benzodiazepine type 1 (BZ1) receptor on the alpha1 subunit of the GABA-A chloride ion channel complex, potentiating the inhibitory effects of GABA.
| Metabolism | Primarily metabolized by CYP3A4 and CYP1A2 (minor), with contributions from CYP2C9 and CYP2D6. |
| Excretion | Renal (primarily as conjugated metabolites, approximately 80-85% of total clearance), fecal (approximately 10-15%), biliary (minor, <5%). |
| Half-life | Terminal elimination half-life is 2.8-3.2 hours in healthy adults. In elderly patients or those with hepatic impairment, half-life may be prolonged to 4-6 hours. |
| Protein binding | Approximately 92-95%, primarily to albumin. |
| Volume of Distribution | 0.8-1.3 L/kg, indicating extensive tissue distribution and penetration into the central nervous system. |
| Bioavailability | Oral: 30-40% (due to first-pass metabolism). Sublingual: 60-75%. Intranasal: 70-85%. |
| Onset of Action | Oral: 15-30 minutes (sublingual formulation: 5-10 minutes). Intranasal: 10-15 minutes. |
| Duration of Action | Oral: 3-4 hours (clinical sedation persists for 1-2 hours, residual effects for up to 6 hours). |
| Molecular Weight | 308.7 |
5 mg orally once daily at bedtime, maximum 10 mg/day.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | Child-Pugh A: 5 mg once daily. Child-Pugh B: 2.5 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 2.5 mg once daily at bedtime, maximum 5 mg/day due to increased sensitivity and risk of falls. |
| 1st trimester | Avoid use due to potential teratogenic effects in animal studies; consider alternative agents. |
| 2nd trimester | Limited human data; use only if benefit outweighs risk, as CNS depressant effects may affect fetal development. |
| 3rd trimester | Avoid use near term due to risk of neonatal withdrawal and respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for ZOLPIMIST (ZOLPIMIST).
| Placental transfer | Crosses placenta readily; fetal serum levels may reach 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low amounts; however, due to risk of sedation and withdrawal in neonates, avoid use in breastfeeding women. If unavoidable, monitor infant for excessive drowsiness, poor feeding, and respiratory depression. |
■ FDA Black Box Warning
BOXED WARNING: Complex sleep behaviors including sleep-driving, sleepwalking, and other activities while not fully awake have been reported. Discontinue immediately if such behaviors occur.
| Serious Effects |
Hypersensitivity to zolpidem or any componentSevere hepatic impairmentMyasthenia gravisHistory of complex sleep behaviors (e.g., sleep-driving) with zolpidem
| Precautions | Complex sleep behaviors (e.g., sleep-driving, sleepwalking) – discontinue immediately if occur, CNS depressant effects – impaired alertness and motor coordination; risk of next-day impairment, Worsening of depression or suicidal ideation, Abuse and dependence potential – use with caution in patients with history of substance abuse, Respiratory depression - use with caution in patients with compromised respiratory function |
| Food/Dietary | Avoid high-fat meals or heavy food immediately before or after administration, as food delays absorption and reduces peak concentration. Grapefruit juice may increase zolpidem levels; avoid concomitant use. No specific dietary restrictions beyond timing of dose. |
Loading safety data…
| Lactation Rating |
| L4 |
| Teratogenic Risk | Zolpidem (ZOLPIMIST) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but adequate human studies are lacking. First trimester: Possible increased risk of congenital malformations, though data are limited. Second and third trimesters: Risk of fetal exposure to CNS depressant effects, including hypotonia, respiratory depression, and withdrawal symptoms in neonates after chronic use. Late third trimester use may lead to neonatal sedation and floppy infant syndrome. |
| Fetal Monitoring | Monitor maternal vital signs, level of sedation, and respiratory rate. Assess fetal heart rate and uterine activity as per routine obstetric care. In neonates exposed near term, monitor for signs of respiratory depression, hypotonia, feeding difficulties, and withdrawal symptoms (irritability, tremors) for at least 48 hours postpartum. Consider prolonged monitoring in cases of high maternal dose or chronic use. |
| Fertility Effects | Limited data in humans. In animal studies, zolpidem did not significantly impair fertility at clinically relevant doses. However, CNS depressant effects may affect libido and sexual function. No specific fertility impairment has been documented in clinical use. |
| Clinical Pearls | Zolpimist (zolpidem tartrate oral spray) is a non-benzodiazepine hypnotic for short-term insomnia treatment. Administer immediately before bedtime on an empty stomach. Effects may be delayed if taken with food. Avoid concurrent alcohol or CNS depressants. Use lowest effective dose, especially in elderly or debilitated patients (5 mg vs 10 mg). Monitor for complex sleep behaviors (sleep-driving, preparing/eating food, making phone calls while asleep). Discontinue if these occur. Tolerance may develop after 2 weeks; limit use to 7-10 days. Withdrawal symptoms possible after prolonged use. Contraindicated in patients with prior complex sleep behavior on zolpidem. |
| Patient Advice | Take this medication right before you get into bed and only if you have a full 7-8 hours to sleep. · Do not take with or immediately after a meal, as food can make it work more slowly. · Avoid drinking alcohol while using this medication, as it can increase side effects. · You may still feel sleepy the next day; avoid driving or hazardous activities until you know how the drug affects you. · Report any unusual behaviors during sleep such as driving, eating, or making phone calls to your healthcare provider immediately. · Do not take more than one dose per night or exceed the prescribed dose. · This medication is for short-term use only (usually 7-10 days); do not stop abruptly without consulting your doctor. · Store at room temperature away from heat and open flame. This product contains alcohol and is flammable. |